RESEARCH ARTICLE

The Arginine Methyltransferase PRMT6 Cooperates with Polycomb Proteins in Regulating HOXA Gene Expression

Claudia Stein*, René Reiner Nötzold*, Stefanie Riedl*, Caroline Bouchard, Uta-Maria Bauer*

Institute for Molecular Biology and Tumor Research (IMT), Philipps-University of Marburg, Marburg, Germany

* These authors contributed equally to this work.
* bauer@imt.uni-marburg.de

Abstract

Protein arginine methyltransferase 6 (PRMT6) catalyses asymmetric dimethylation of histone H3 at arginine 2 (H3R2me2a), which has been shown to impede the deposition of histone H3 lysine 4 trimethylation (H3K4me3) by blocking the binding and activity of the MLL1 complex. Importantly, the genomic occurrence of H3R2me2a has been found to coincide with histone H3 lysine 27 trimethylation (H3K27me3), a repressive histone mark generated by the Polycomb repressive complex 2 (PRC2). Therefore, we investigate here a putative crosstalk between PRMT6- and PRC-mediated repression in a cellular model of neuronal differentiation. We show that PRMT6 and subunits of PRC2 as well as PRC1 are bound to the same regulatory regions of rostral HOXA genes and that they control the differentiation-associated activation of these genes. Furthermore, we find that PRMT6 interacts with subunits of PRC1 and PRC2 and that depletion of PRMT6 results in diminished PRC1/PRC2 and H3K27me3 occupancy and in increased H3K4me3 levels at these target genes. Taken together, our data uncover a novel, additional mechanism of how PRMT6 contributes to gene repression by cooperating with Polycomb proteins.

Introduction

In mammals nine Protein Arginine Methyltransferases (PRMT1-9) have been identified, which transfer a methyl group from the ubiquitous cofactor S-adenosyl-L-methionine to the terminal guanidino nitrogens of arginine residues in target proteins. Subsequent to mono- methyl-arginine, type I PRMTs form asymmetric (ω-NGω-N') dimethyl-arginine, whereas type II enzymes give rise to symmetric (ω-NGω-NG') dimethyl-arginine [1]. Methylation of an arginine does not alter the positive charge of the guanidinium side chain, but changes its structure and the affinity between the substrate and its binding partners resulting in promotion or inhibition of interactions [2]. A multitude of nuclear and cytoplasmic proteins are substrates of arginine methylation, by which means PRMTs regulate a wide range of essential cellular functions [2].
PRMT6 was identified in 2002 by using the high sequence conservation of the PRMT catalytic domain for homology search in the human genome [3]. The enzyme belongs to the type I enzymes and prefers mono-methylated arginine as substrate [4,5]. In agreement with its primary nuclear localisation, PRMT6 methylates chromatin proteins. Similar to other PRMTs, PRMT6 typically targets glycine-arginine rich (GAR) motifs in substrates [6]. Accordingly, PRMT6 has been shown to modify HMGA1 and fibrillarin suggesting its involvement in chromatin architecture, splicing and rRNA processing [3,7,8]. However, PRMT6 methylates also non-GAR motifs, such as in the Tat protein of HIV1 leading to restriction of viral transcription and replication [9]. Automethylation of PRMT6 in a non-GAR motif results in increased protein stability and therefore activity [10]. Interestingly, PRMT6 was also reported to modify the DNA polymerase β thereby enhancing base excision repair [11] and the androgen receptor contributing to neurodegeneration [12]. Furthermore, PRMT6 acts as a histone methyltransferase on all four core histones, such as H3 at R2 [5,13], H2A at R29 [14] and H3 at R42 [15], thus leading to either transcriptional repression or activation. Due to transcriptional repression of tumor suppressor genes, PRMT6 promotes cell proliferation and blocks senescence [16–19].

The mechanism of transcriptional repression via asymmetric dimethylation of H3R2 (H3R2me2a) has intensively been studied. The H3R2me2a mark is a negative regulator of H3K4 trimethylation (H3K4me3), as it inhibits the activity of the H3K4 methyltransferase MLL1 and blocks recruitment of the MLL-complex subunit WDR5 to histone H3 [5,13,20]. Crystal structure analysis of WDR5 supports this antagonism between the two marks, as hydrogen bonding between the WD40 domain of WDR5 and the guanidino group of R2 is disturbed by asymmetric dimethylation [21,22]. Accordingly, overexpression of PRMT6 leads to global reduction of H3K4me3 levels and ChIP (chromatin immunoprecipitation) analysis showed a countercorrelation between the genomic occurrence of H3K4me3 and H3R2me2a [5,13]. Given that H3K4me3 generally marks the TSS (transcriptional start site) of actively transcribed as well as paused genes, reduction of the H3K4me3 levels by PRMT6-mediated H3R2me2a causes transcriptional repression, which has been demonstrated for a selection of PRMT6 target genes, such as HOX genes, MYC-target genes and TSP-1 [5,13,20,23]. In agreement with this, H3R2me2a is not enriched at promoters of active genes and occurs at silent genomic regions, such as pericentromeric chromatin [24,25]. Apart from interfering with the deposition of H3K4me3, H3R2me2a might also impair the recognition of H3K4me3, as some readers of H3K4me3 are blocked by the presence of an adjacent H3R2me2a mark, for example the TFIID subunit TAF3 and the NURF subunit BPTF [20,26,27]. However, it is not clear to which extent H3K4me3 and H3R2me2a might coexist on the same histone tail.

Vice versa, the enzymatic activity of PRMT6 is influenced as well by neighbouring histone modifications, as the presence of the H3K4me3 mark reduces the ability of PRMT6 to modify R2 [5,13,20]. In contrast, premodification of H3 peptides with K27 di- and trimethylation (H3K27me2 / H3K27me3) enhances the methyltransferase activity of PRMT6 towards R2 [5]. Further, the genomic occurrence of H3R2me2a and H3K27me3 coincides at a distinct set of promoters, which are transcriptionally inactive [28–30]. H3K27me3 is a repressive histone mark, predominantly mediated by the EZH2 protein and deposited at facultative heterochromatin as well as silent genes, in particular differentiation-associated genes and tumor suppressor genes [31]. EZH2 together with the subunits EED, SUZ12 and RbAp48 comprises the canonical Polycomb repressive complex 2 (PRC2), which is able to associate with several other proteins allowing the formation of diverse complexes [31–34]. PRC2 cooperates with a second complex, the Polycomb repressive complex 1 (PRC1). PRC1 consists of four core subunits, which have several homologues in mammals giving rise to various complex combinations: CBX (chromobox) proteins, PH (Polyhomeotic) proteins, PSC (Posterior sex combs) proteins and SCE (Sex combs extra) proteins [35]. The SCE proteins, RING1A and RING1B, account
for the enzymatic activity of PRC1 by mono-ubiquitylating H2A at K119. CBX-containing
PRC1 complexes recognise the H3K27me3 mark deposited by PRC2 via the chromodomain of
the CBX subunit. Together, PRC1 and PRC2 achieve the stable transcriptional repression of
PRC target genes.

Given that both H3K27me3 and H3R2me2a are repressive histone marks and co-occur at a
subset of gene promoters, we asked here whether PRMT6 influences PRC-mediated repression
differentiation-associated target genes. We find that in NT2/D1 cells, a model for neuronal
differentiation, PRMT6 and subunits of PRC1 as well as PRC2 are bound to the same regulatory
regions of rostral HOXA genes and diminish their transcriptional activation. Further, we
show that PRMT6 interacts with subunits of the PRC1 and PRC2 complexes. Interestingly,
depletion of PRMT6 results on the one hand in declined PRC1/PRC2 recruitment as well as
H3K27me3 levels and on the other hand in increased H3K4me3 levels at the rostral HOXA
genes. Taken together, our data uncover a novel, additional mechanism of how PRMT6 con-
tributes to gene repression by cooperating with Polycomb proteins.

Materials and Methods

Cell lines, antibodies and plasmids
NT2/D1 and HEK293 cells were maintained in DMEM supplemented with 10% fetal calf
serum (FCS, Gibco/BRL) at 37°C and 5% CO2. To induce neuronal differentiation of NT2/D1
cells with 0.1 μM ATRA (all-trans retinoic acid from Sigma) we followed the protocol
described elsewhere [36].

The following antibodies were employed: rabbit affinity-purified anti-PRMT6 was produced
using His-tagged proteins corresponding to amino acids 60–375 of human PRMT6; anti-H3
(05–499) from Upstate; anti-H3R2me2a (04–808), anti-H3K27me3 (07–449) and anti-
H3K4me3 (07–473) from Millipore; anti-Myc (9E11), anti-GFP (G6539), anti-Flag (M2)
(F3165), mouse IgG (I5381) and rabbit IgG (I5006) from Sigma; anti-CDK2 (sc-163) from
Santa Cruz; anti-CBX8 (A300-882A) from Bethyl Laboratories; anti-HPH1 [37], anti-HPH2
[38], anti-BMI1 [39], anti-CBX8 [40], anti-EZH2 [41], anti-RING1A [42], anti-RING1B [37]
were kindly provided. The expression construct for HPH1 (Rae28) is described in [43]. The
expression construct of Myc-HPH2 was a gift from H. Koseki (RIKEN Yokahama Institute).
The expression constructs for CBX2, CBX4 and CBX8 were published by [40]. Flag-EZH2 was a
gift from D. Reinberg.

Plasmid and siRNA transfection
Short interfering RNA (siRNA) oligonucleotide duplexes were obtained from Eurogentec or
Dharmacon for targeting PRMT6, CBX8 and EZH2, respectively. The target sequences of siR-
NAs are listed in the Supporting Information (S1 Text). Transfections of siRNAs in NT2/D1
cells were performed with the aid of Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s instructions. Plasmids were transfected using the PEI or calcium phosphate
methods.

Reverse transcription quantitative PCR (RT-qPCR) and chromatin
immunoprecipitation quantitative PCR (ChIP-qPCR)
Total RNA was isolated using Seqlab RNA-Mini-Kit according to the protocol and applied
(0.5–1 μg) to reverse transcription (RT) by incubation with oligo(dT)17 primer and M-MLV
reverse transcriptase (Invitrogen), as recommended by the manufacturer. ChIP experiments
were performed as described in [5]. The cDNA and eluted chromatin were subjected to
qPCR analysis gene-specific primers listed in the Supporting Information (S1 Text). Quantitative PCR was performed using Absolute QPCR SYBR Green Mix (Thermo Scientific) and the Mx3000P real-time detection system (Agilent). For RT-qPCR UBIQUITIN gene transcription was used for normalisation. ChIP-qPCR results were calculated as % input. All experiments were performed at least three times and each experiment in triplicate. Reproducible and representative data sets are shown. Error bars represent mean +/- S.D. of triplicate reactions.

Gel filtration analysis

To prepare whole-cell extracts, cells were lysed in IPH-buffer (150 mM NaCl, 5 mM EDTA, 0.5% (v/v) NP-40, 50 mM Tris, pH 8.0) including protease inhibitors and incubated 30 minutes at 4°C under rotation. DNA was digested using Benzonase for at least one hour at 4°C. Subsequently, proteins (3–5 mg) were separated on a Superose 6 HR 10/30 using the ÄktaTM Purifier 10 System (GE Healthcare) at a flow rate of 0.7 ml/minute and a pressure of 0.3–0.4 MPa. Six ml fractions were collected and either analysed by Western blot or used in co-immunoprecipitation followed by Western blot.

Results

PRMT6 and the PRC complexes occupy the same regulatory regions of HOXA genes during neuronal differentiation

The human embryonal carcinoma (EC) cell line NT2/D1 represents a well-characterised model system to study the regulation of the HOXA gene cluster (Fig 1A for illustration of the HOXA cluster) [36,44–46]. Upon all-trans retinoic acid (ATRA) treatment NT2/D1 cells differentiate along the neuronal lineage, which is accompanied by transcriptional upregulation of rostral (3’) HOXA genes HOXA1-5, whereas no or only subtle changes in expression of caudal (5’) HOXA genes HOXA9-13 have been observed [47,48]. These ATRA-induced transcriptional changes have been reported to be accompanied by a loss of PRC1 and PRC2 recruitment and a reduction of H3K27me3 levels at the rostral HOXA genes [36]. Importantly, the HOXA2 gene is also a well-established target gene of PRMT6-mediated repression [5,20]. The finding that H3R2me2a and H3K27me3 coincide at human promoter regions [28] suggests a potential positive crosstalk between PRMT6- and Polycomb-mediated transcriptional repression. To further investigate PRMT6-occupied sites at HOXA genes and how these relate to the binding mode of PRC1 and PRC2 at the gene cluster, we employed ChIP (chromatin immunoprecipitation) analysis of undifferentiated, 2 and 6 days ATRA-differentiated NT2/D1 cells. We determined the occurrence of PRMT6, its histone modification H3R2me2a, CBX8 as a representative for PRC1, EZH2 as a representative for PRC2 and H3K27me3 at regulatory regions and promoters of various rostral HOXA genes, such as HOXA1, A2 and A5, as well as the caudal HOXA genes, HOXA9 and A10. We found that PRMT6 and H3R2me2a are present at the regulatory regions of all investigated HOXA genes in undifferentiated cells and that their occurrence remained unchanged at the HOXA9 and A10 gene promoters throughout the time-course of differentiation (Fig 1B). In contrast, at the rostral genes, HOXA1, A2 and A5, their occurrence was successively lost during differentiation (Fig 1B). This recruitment pattern of PRMT6 and H3R2me2a at the different HOXA genes coincided with the binding of CBX8 and EZH2 and the occurrence of H3K27me3. Taken together, these data identify the HOXA gene locus as a common recruitment site for PRMT6, Polycomb proteins and their corresponding histone modifications in NT2/D1 cells.
PRMT6 and PRC complexes repress the differentiation-associated transcriptional activation of rostral HOXA genes

The genomic co-occurrence of PRMT6 and Polycomb proteins during neuronal differentiation of NT2/D1 cells suggests a potential positive crosstalk between the two repressive pathways in the transcriptional regulation of HOXA genes. We therefore aimed to investigate whether the presence of PRMT6 represses transcription of HOXA genes in NT2/D1 cells and how PRC complexes influence transcription of these genes. To this end, we initially confirmed by RT-qPCR the ATRA-driven transcriptional effects on rostral and caudal HOXA gene expression in NT2/D1 cells. As expected, upon ATRA treatment HOXA1, A2, A5, A9 and A10 genes were transcriptionally activated, whereas HOXA9 and A10 transcript levels remained unchanged (Fig 2A).

Next, we established siRNA-mediated depletion of PRMT6 in these cells by transfection of PRMT6 siRNAs. Forty-eight hours post transfection, cells were left untreated (-) or treated for 2 days (+) with 0.1 μM ATRA. Subsequently, total RNA was prepared and analysed in triplicates by RT-qPCR for transcript levels of PRMT6, HOXA1, A2, A5, A9 and A10 normalised to UBIQUITIN transcription. Error bars represent mean +/- S.D. of the triplicates. Transcript levels of untreated and siControl-transfected NT2/D1 cells were set to 1. (Fig 2B)
siRNA targeting PRMT6 (siPRMT6) or control siRNA (siControl). Subsequently, RT-qPCR analysis was performed to measure transcript levels of PRMT6 and the various HOXA genes in untreated as well as 2 days ATRA-treated NT2/D1 cells. Thereby, an efficient knockdown of PRMT6 was observed and we further showed that transcript levels of PRMT6 remain unchanged upon ATRA-induced differentiation in control cells (Fig 2B). Consistent with our observations in wild type NT2/D1 cells (Fig 2A), HOXA1 and A2 genes were transcriptionally induced (HOXA5 weakly), while HOXA9 and A10 transcript levels remained constant upon ATRA treatment in siControl transfected cells (Fig 2B). Interestingly, depletion of PRMT6 did not significantly influence the transcriptional activity of the rostral as well as caudal HOXA genes in undifferentiated cells. However, it resulted in increased transcriptional activation of HOXA1, A2 and A5 genes upon ATRA treatment compared to control transfected cells, whereas HOXA9 and A10 transcript levels were not altered (Fig 2B). Furthermore, the observations for the rostral HOXA genes were confirmed using alternative siRNAs directed against PRMT6 (S1 Fig). Taken together, these data suggest that PRMT6 acts as a transcriptional repressor of rostral HOXA genes by fine-tuning the transcriptional activation of these genes in response to ATRA-induced neuronal differentiation of NT2/D1 cells.

We next asked whether PRC complexes, similar to PRMT6, are important for modulating the expression of HOXA genes during differentiation. Therefore, we additionally established siRNA-mediated depletion of CBX8 and EZH2 in NT2/D1 cells. An efficient knockdown was detected by Western blot analysis for all three proteins (Fig 3A). Similar to the effects upon PRMT6 depletion, RT-qPCR analysis revealed that depletion of CBX8 and EZH2 resulted in an increased transcriptional activation of HOXA1, A2 and A5 genes in response to ATRA compared to control transfected cells, while the basal transcript levels of the rostral HOXA genes remained unaltered in the absence of ATRA (Fig 3B). As observed upon PRMT6 depletion, the transcription of caudal HOXA genes, HOXA9 and A10, was not significantly affected by depletion of CBX8 and EZH2, neither in undifferentiated nor in differentiated cells (data not shown). These results indicate that PRMT6, PRC1 (represented by the CBX8 subunit) and PRC2 (represented by the EZH2 subunit) function as direct transcriptional repressors of rostral HOXA genes to control their differentiation-associated activation in NT2/D1 cells. Although transcriptional activation of these target genes is accompanied by reduced PRMT6, PRC1 and PRC2 occupancy as well as H3R2me2a and H3K27me3 levels at the corresponding regulatory regions (Fig 1B), PRMT6- and Polycomb-dependent repression still seem to be responsible for constraining rostral HOXA gene activation. Our observations suggest that PRMT6 and PRC1/PRC2 are not required for maintaining the transcriptional repression of HOXA genes in the undifferentiated NT2/D1 cells, but rather confine their ATRA-induced gene activation.

**PRMT6 interacts with PRC1 and PRC2 subunits**

Given our observation that PRMT6 and H3R2me2a binding sites are as well occupied by PRCs and H3K27me3 at the HOXA cluster and given that the occurrence of both histone modifications correlates at silent gene promoters [28], we asked whether these enzymes and complex subunits physically interact. To address this question we performed CoIP (co-immunoprecipitation) assays to investigate protein-protein interactions between PRMT6 and subunits of PRC1 as well as PRC2 complexes. We initially overexpressed several core components of PRC1 complexes including the human PH homologues HPH1 and HPH2 as well as the CBX variants CBX2, CBX4 and CBX8. Immunoprecipitation of endogenous PRMT6 followed by Western blot staining to detect the exogenous PRC1 subunits revealed that HPH1, HPH2, CBX4 and CBX8 interact with PRMT6, whereas no binding was observed between PRMT6 and CBX2 (Fig 4A and 4B). We further confirmed the interactions between PRMT6 and the PH
Fig 3. Rostral HOXA genes are common target genes of PRMT6- and PRC-mediated repression. (A) NT2/D1 cells were transfected with control siRNAs (siControl) or siRNAs directed against PRMT6 (siPRMT6 = equal mixture of siPRMT6_1 and siPRMT6_2), CBX8 (siCBX8) or EZH2 (siEZH2).
homologues on endogenous protein level (Fig 4C). In addition, CoIP-assays for the PSC homologues BMI1 and MEL18 indicated that endogenous BMI1 associates with PRMT6 (Fig 4C), whereas MEL18 showed no or only very weak interaction with the arginine methyltransferase (S2 Fig). The same results were obtained after addition of ethidium bromide in the IPs indicating that these interactions are not DNA-mediated (data not shown). To answer the question of whether the interaction with PRC1 components is a general characteristic of arginine methyltransferases, we performed similar analyses for PRMT1 and PRMT4. Thereby we demonstrated that these two PRMTs do not interact with BMI1 or HPH2 (S3 Fig) suggesting that the association with PRC1 subunits is a specific feature of PRMT6.

As several PRC1 complexes with alternate subunit composition have been identified in mammals [49,50], we next performed Superose 6 gel filtration analysis to determine whether PRMT6 associates with such PRC1-type complexes. We found that endogenous PRMT6 elutes in molecular weight fractions (maximum in fraction no. 12) of approximately 440 kD (Fig 4D, S4 Fig), which is a molecular weight higher than expected from its monomeric (42 kD) or dimeric size. Notably, PRMT6 co-eluted with endogenous (Fig 4D) and exogenous (S4 Fig) PRC1 components, such as HPH2, CBX8, BMI1, RING1A and RING1B. CoIP assays of the PRMT6-containing gel filtration fractions indicated that PRMT6 interacts with CBX8 and HPH2 in these high-molecular weight fractions (S5 Fig) suggesting that PRMT6 stably associates with the CBX-containing PRC1-type complex.

To examine whether PRMT6 interacts with PRC2 subunits, in particular EZH2, we transiently overexpressed Flag-tagged EZH2. As shown in Fig 4E, endogenous PRMT6 co-immunoprecipitated with exogenous as well as endogenous EZH2 (Fig 4E). Furthermore, gel filtration analysis showed that Flag-tagged EZH2 mainly co-elutes with PRMT6 in fraction no. 12, although EZH2 was also present in higher molecular weight fractions (no. 9 and 10) not containing PRMT6 (Fig 4F). We found that PRMT6 co-immunoprecipitates with EZH2 in such gel filtration fractions, in which both proteins co-eluted from the column (S6 Fig). Together these findings indicate that PRMT6, even though it does not seem to be an integral component of the core PRC complexes, transiently associates with PRC subunits as well as PRC complexes and thereby might influence the repressive capacity of these complexes.

PRMT6 influences PRC-mediated gene silencing at the rostral HOXA genes locus

As PRMT6 binding sites overlap with those of the PRC subunits CBX8 and EZH2 at regulatory regions within the HOXA gene locus and PRMT6 physically interacts with both proteins, we examined whether PRMT6 impacts Polycomb-dependent repression of the rostral HOXA genes. Therefore, we performed ChIP analysis of PRC subunits CBX8 and EZH2 as well as H3K27me3 at rostral HOXA genes in siPRMT6- or siControl-transfected NT2/D1 cells, which were either undifferentiated or ATRA-differentiated. The occupancy of PRMT6 was reduced at the HOXA2 and A5 gene promoters in the PRMT6-depleted conditions (Fig 5A). Interestingly, binding of CBX8 and EZH2 to the HOXA2 and A5 gene promoters was diminished upon depletion of PRMT6 both in the absence and presence of ATRA (Fig 5A). These events coincided with a decrease in H3K27me3 levels (Fig 5B) suggesting that PRMT6 positively
Fig 4. PRMT6 interacts with subunits of PRC1 and PRC2. (A) HEK293 cells were transfected with untagged HPH1 or Myc-tagged HPH2 constructs (OE = overexpressed) and harvested 48 hours after transfection. Protein extracts were subjected to immunoprecipitation using antibodies against PRMT6 (α-PRMT6) or isotype-specific IgG as control. Inputs (2%) and precipitates were subjected to Western blot analysis using antibodies against HPH1 (α-HPH1), Myc-tag (α-Myc for HPH2 detection) and PRMT6 (α-PRMT6). The asterisk indicates an unspecific signal in the α-PRMT6 staining. (B) HEK293 cells were transfected with GFP-tagged CBX2, CBX4 and CBX8 constructs (OE = overexpressed) and harvested 48 hours after transfection. Protein extracts were subjected to immunoprecipitation using antibodies against PRMT6 (α-PRMT6) or as control isotype-specific IgG. Inputs (2%) and precipitates were subjected to Western blot analysis using antibodies against GFP (α-GFP for CBX detection) and PRMT6 (α-PRMT6). (C) For the detection of endogenous interactions, HEK293 cells were transfected with GFP-tagged CBX2, CBX4 and CBX8 constructs (OE = overexpressed) and harvested 48 hours after transfection. Protein extracts were subjected to immunoprecipitation using antibodies against PRMT6 (α-PRMT6) or as control isotype-specific IgG. Inputs (2%) and precipitates were subjected to Western blot analysis using antibodies against HPH1 (α-HPH1), HPH2 (α-HPH2), BMI1 (α-BMI1), RING1A and RING1B, endogenously. The column was calibrated using standard protein markers. Accordingly, the molecular weight included in the fractions and the void volume (V0) are indicated. (E) For the detection of endogenous and exogenous interaction between PRMT6 and EZH2, HEK293 cells were either not transfected or transfected with Flag-tagged EZH2 construct (OE = overexpressed). Subsequently, protein extracts were subjected to immunoprecipitation using antibodies against PRMT6 (α-PRMT6) or isotype-specific IgG as control. Input protein extracts were subjected to immunoprecipitation using antibodies against GFP (α-GFP for CBX detection) and PRMT6 (α-PRMT6). (C) For the detection of endogenous interactions, HEK293 cells were transfected with GFP-tagged CBX2, CBX4 and CBX8 constructs (OE = overexpressed) and harvested 48 hours after transfection. Protein extracts were subjected to immunoprecipitation using antibodies against PRMT6 (α-PRMT6) or as control isotype-specific IgG. Inputs (2%) and precipitates were subjected to Western blot analysis using antibodies against HPH1 (α-HPH1), HPH2 (α-HPH2), BMI1 (α-BMI1) and PRMT6 (α-PRMT6). (D) For size fractionation by gel filtration chromatography, whole-cell protein extracts were prepared from HEK293 cells. Protein extracts were applied to a Superose 6 column and 6 ml fractions were collected. Five % of each fraction (no. 6 – 17) were analysed by Western blot using the indicated antibodies to detect PRMT6, HPH2, CBX6, BMI1, RING1A and RING1B, endogenously. The column was calibrated using standard protein markers.
influences the deposition of this mark, possibly via its association with the PRC1 complex and EZH2. To test the hypothesis that PRMT6-mediated deposition of H3R2me2a might directly promote the catalytic activity of EZH2, we performed in vitro methyltransferase assays using recombinant PRC2 complex in the presence of unmodified and premodified H3 peptides. To first validate the assay we determined the methylation activity of EZH2 towards unmodified and H3K27me3-premodified peptides. While a methylation product was detected by autoradiography for the unmodified H3 peptide, no signal was obtained when the H3K27me3-premodified peptide was employed as a substrate confirming that H3K27 is the major methylation site of recombinant PRC2 complex in our assay (S7 Fig). Premodification at R2 either by mono-methylation or asymmetric dimethylation did not enhance the activity of EZH2 arguing against a positive crosstalk at the level of these histone modifications (S7 Fig). In agreement with previous observations [5], we found that depletion of PRMT6 results in increased levels of H3K4me3 at the HOXA2 and A5 gene promoters in NT2/D1 cells (Fig 5C). As H3K4me3 has been reported to inhibit recognition of the H3 N-terminus by PRC2 and thereby the PRC2 activity [51], PRMT6 might promote the occurrence of H3K27me3 and Polycomb-mediated repression by constraining the levels of H3K4me3.

Together, these data uncover a novel and additional mechanism of how PRMT6 contributes to gene repression during cellular differentiation. Apart from counteracting the occurrence of H3K4me3, PRMT6 interacts with components of PRC1/PRC2 and facilitates chromatin binding of these subunits and the deposition of H3K27me3. Our observations suggest that PRMT6- and PRC1/PRC2-mediated repression mechanisms cooperate in fine-tuning and controlling appropriate timing and magnitude of ATRA-induced transcriptional activation of rostral HOXA genes.

Discussion

The PRMT family member PRMT6 catalyses asymmetric dimethylation of histone H3 at arginine 2 and thereby causes transcriptional repression of PRMT6-bound genes by antagonising the deposition of the active histone mark H3K4me3 by the MLL1 complex [5,13,20,23]. This mechanism of transcriptional repression has been shown to be relevant during differentiation processes, such as PRMT6 acts as a co-repressor of the transcription factor RUNX1 thereby inhibiting megakaryocytic genes in hematopoietic progenitor cells and later the erythroid-specific gene expression program during megakaryocytic differentiation [29,30]. Furthermore, PRMT6 influences the expression of pluripotency and differentiation markers in embryonic stem cells [52]. Our own observations revealed that PRMT6 associates with differentiation-associated genes in neural progenitor cells [5], in line with high expression levels of PRMT6 in the developing mouse brain [53]. Therefore, we studied here the repressive role of PRMT6 and its functional relationship with neighbouring histone marks during neural differentiation using the EC model of NT2/D1 cells, which predominantly differentiate along the neuronal lineage upon exposure to ATRA.

H3R2me2a co-occurs at the genomic level with H3K27me3, a well-established repressive histone mark [28–30]. In addition, the presence of H3K27me3 and its writer as well as reader complexes (PRC2 and PRC1) have been described in detail at the HOXA gene cluster in NT2/D1 cells [36,48,54]. In undifferentiated cells, the HOXA gene locus is marked by high levels of H3K27me3 and bound by EZH2 (PRC2) as well as CBX8 (PRC1). Upon ATRA-induced
neuronal differentiation, H3K27me3 and PRCs are specifically displaced from the rostral HOXA genes (HOXA1-5) in agreement with their transcriptional activation, whereas the caudal HOXA genes (HOXA9-13) keep high amounts of this repressive mark and the PRCs and unchanged expression levels [36,48,55]. Interestingly, PRMT6 and its histone mark H3R2me2a show a binding pattern at the HOXA cluster in undifferentiated and differentiating NT2/D1 cells similar to the one of H3K27me3 and the PRCs indicating that this locus is appropriate for studying a putative crosstalk between the PRMT6 and Polycomb proteins in target gene repression.

To elucidate the potential impact of PRMT6 as well as the PRCs on the transcriptional activity of the HOXA locus, we depleted the relevant enzymes and representative subunits of the complexes. We found that PRMT6 and PRC1/2 did not influence the expression of caudal HOXA genes, neither in undifferentiated nor in differentiating NT2/D1 cells. This is in agreement with previous observations showing that PRC1/2 binding does not strictly correlate with transcriptional silencing, but also occurs at transcriptionally active genes, which seems to hold true also for PRMT6 [36]. Furthermore, not all target genes of PRC1 and PRC2 are derepressed upon PRC depletion, but are thought to have acquired an additional, more permanent silencing, such as DNA methylation or higher order chromatin structure, which makes the stable presence of PRC1/2 dispensable [31,36]. However, we surprisingly observed that PRMT6 and PRC1/2 specifically restrict the transcriptional activation of rostral HOXA genes in differentiating NT2/D1 cells, although the occupancy of PRMT6, PRC1/2 as well as their histone marks was reduced at these gene promoters upon differentiation. This further supports the view that binding of PRMT6 and PRCs is diminished at differentiation-specific genes to enable their transcriptional induction, while they still seem to be required for constraining and fine-tuning the transcriptional response.

Given that PRMT6 and subunits of PRC1 and PRC2 coincide in their binding pattern at rostral HOXA genes and have a similar repressive influence on the ATRA-induced transcriptional activation of these genes, we investigated whether PRMT6 would directly regulate PRC-dependent repression. Depletion of PRMT6 resulted in reduced occupancy of CBX8 and EZH2 at HOXA2 and A5 gene promoters and in decreased levels of H3K27me3, independently of the differentiation status of the cells. In differentiating NT2/D1 cells these observations are in agreement with an enhanced ATRA-mediated transcriptional activation of HOXA2 and A5, whereas the basal activity of these genes was not derepressed in undifferentiated cells. These results imply that PRMT6- and PRC-mediated repression cooperate in the transcriptional regulation of cell-fate genes. Although we found that PRMT6 is able to physically interact with several subunits of PRC1 and with EZH2, we hypothesise that PRMT6 is not responsible for the chromatin recruitment of PRCs via protein-protein interactions. We postulate that PRMT6 associates with PRC components at the chromatin and stimulates a histone modification landscape, such as increased H3R2me2a levels and decreased H3K4me3 levels, in the vicinity of PRC binding sites, which stabilises PRC binding and enhances the catalytic activity of EZH2.

In agreement with this model, our data indicate that PRMT6 is not a stable component of core cell fate genes.
PRMT6 Cooperates with Polycomb Proteins in Gene Expression

PRMT6 complexes, but rather support that PRMT6 transiently associates with PRC subunits and complexes to regulate their repressive capacity.

Given the complex interplay between different histone modifications and the fact that a pre-existing modification can promote or inhibit the subsequent occurrence of another histone mark, such as H3R2me2a counteracting the deposition of H3K4me3 (5, 13), we asked whether the positive crosstalk between PRMT6 and PRCs is mediated via the H3R2me2a mark. Therefore, we assayed the catalytic activity of EZH2 on unmodified as well as H3R2me2a-premodified H3 peptides. Monomethylation or asymmetric dimethylation at R2 did not enhance the activity of EZH2 indicating that PRMT6 does not directly influence the EZH2 activity via depositioning the H3R2me2a mark. However, H3K4me3 levels were increased at the HOXA2 as well as A5 gene promoter in PRMT6-depleted NT2/D1 cells, in particular upon ATRA treatment. As H3K4me3 has been reported to inhibit the recognition of histone H3 N-terminus by PRC2 and thereby the PRC2 activity [51], we hypothesise that PRMT6 promotes the occurrence of H3K27me3 and consequently the recruitment of CBX8 at rostral HOXA genes in an indirect manner via associating with PRC complexes and thereby restricting the occurrence and magnitude of H3K4me3.

In summary, we postulate a model, in which neither PRMT6 nor PRCs are necessary for maintaining the transcriptional status (low basal activity) of the HOXA gene cluster in undifferentiated NT2/D1 cells despite their presence at the chromatin. This situation also applies to the caudal HOXA genes in differentiating cells suggesting that here additional, more permanent silencing mechanisms have been acquired. However, upon ATRA treatment rostral HOXA genes are transcriptionally activated, which is facilitated by an increase in H3K4me3 levels via MLL1 complex recruitment with the concomitant reduction of PRMT6 and PRC1/2 recruitment and their corresponding histone marks. Even during this transcriptional activation a balance of activating and silencing mechanisms seem to be necessary to enable an adequate transcriptional response, since PRMT6 and PRCs are important for constraining the ATRA-mediated transcriptional response of rostral HOXA genes. Altogether, our results confirm the previously reported countercorrelation between PRMT6 and MLL1 activities and uncover a novel cooperation between PRMT6- and PRC-mediated repression.

Supporting Information

S1 Fig. Alternative siRNAs targeting PRMT6 confirm the function of PRMT6 in repressing the ATRA-mediated transcriptional activation of rostral HOXA genes. NT2/D1 cells were transfected with control siRNAs (siControl) or 8 alternative siRNAs directed against PRMT6 (including the mixture of siPRMT6_1 and siPRMT6_2, which was used in Fig 3 and Fig 5). Forty-eight hours post transfection cells were left untreated (-) or treated for 2 days (+) with 0.1 μM ATRA. Subsequently, total RNA was prepared and analysed in triplicates by RT-qPCR for transcript levels of PRMT6, HOXA1, A2 and A5 normalised for UBIQUITIN transcription. Error bars represent mean +/- S.D. of the triplicates. Transcript levels of untreated and siControl-transfected NT2/D1 cells were set to 1. (TIF)

S2 Fig. PRMT6 does not or only weakly interact with MEL18. HEK293 cells were transfected with GFP-tagged MEL18 construct and harvested 48 hours after transfection. Protein extracts were subjected to immunoprecipitation using antibodies for PRMT6 (α-PRMT6) or as controls beads alone as well as isotype-specific IgG. Input (2%) and precipitates were subjected to Western blot analysis using antibodies against GFP (α-GFP for MEL18 detection) and PRMT6 (α-PRMT6). (TIF)
S3 Fig. PRMT1 and PRMT4 do not interact with subunits of the PRC1 complex, such as BMI1 and HPH2. HEK293 protein extracts were subjected to immunoprecipitation using antibodies for PRMT1 (α-PRMT1), PRMT4 (α-PRMT4) or as controls beads alone as well as isotype-specific IgG. Input (2%) and precipitates were subjected to Western blot analysis using antibodies against BMI1 (α-BMI1), HPH2 (α-HPH2), PRMT1 (α-PRMT1) and PRMT4 (α-PRMT4). The asterisk indicates the specific signals for the PRMT4 protein.

(TIF)

S4 Fig. PRMT6 co-elutes with the PRC1 subunits HPH2 and CBX8 in the same high molecular weight fractions. For size fractionation by gel filtration chromatography, HEK293 cells were transfected with GFP-tagged CBX8 and Myc-tagged HPH2 constructs. Subsequently whole-cell protein extracts were applied to a Superose 6 column and 6 ml fractions were collected. Five % of each fraction (no. 6–15) were analysed by Western blot using the indicated antibodies to detect GFP (α-GFP for CBX8 detection), Myc-tag (α-Myc for HPH2 detection) and PRMT6 (α-PRMT6). The column was calibrated using standard protein markers. Accordingly, the molecular weight included in the fractions and the void volume (V0) are indicated.

(TIF)

S5 Fig. PRMT6 stably interacts with CBX8 and HPH2 in co-elution gel filtration fractions. HEK293 cells were transfected with GFP-tagged CBX8 and Myc-tagged HPH2 constructs. Whole-cell protein extracts (WCE) and the corresponding Superose 6 gel filtration fractions (no. 6–15) were subjected to immunoprecipitation using antibodies against PRMT6 (α-P6, α-PRMT6) or as control isotype-specific IgG (only for WCE). Input (2%) of WCE and precipitates were analysed by Western blot using antibodies against GFP (α-GFP for CBX8 detection), Myc-tag (α-Myc for HPH2 detection) and PRMT6 (α-PRMT6).

(TIF)

S6 Fig. PRMT6 stably interacts with EZH2 in co-elution gel filtration fractions. HEK293 cells were transfected with Flag-tagged EZH2 construct. Whole-cell protein extract (WCE) and the corresponding Superose 6 gel filtration fractions (no. 6–16) were subjected to IP using antibodies against PRMT6 (α-P6, α-PRMT6) or as control isotype-specific IgG (only for WCE). Input (2%) of WCE and precipitates were subjected to Western blot analysis using antibodies against Flag-tag (α-Flag for EZH2 detection) and PRMT6 (α-PRMT6).

(TIF)

S7 Fig. The catalytic activity of recombinant PRC2 is not enhanced by R2me2a-premodification of H3. Recombinant PRC2 complex (400 ng) and 4 μg of either unmodified, R2me1, R2me2a or K27me3 premodified H3 peptides (aa 1–30) were incubated in the presence or absence of [13C-methyl]-SAM overnight at 30°C. Subsequently, the methyltransferase reactions were analysed by SDS-PAGE, blotting and autoradiography. Ponceau S staining of the blot was used as loading control for the different H3 peptides.

(TIF)

S1 Text. Supporting Information Materials and Methods.

(DOCX)

Acknowledgments

We are grateful to Pierre Boulanger, Kristian Helin, Haruhiko Koseki, Tom Kerppola, Danny Reinberg, Yoshihiro Takihara and Miguel Vidal for their valuable gifts of plasmids and antibodies. We thank Inge Sprenger for technical assistance. We thank all members of the U.M.B.
laboratory for their suggestions and help. This work was supported by the Deutsche Forschungsgemeinschaft (DFG) through project grant numbers TRR81/A3 and BA2292/1-3 to U. M.B.

**Author Contributions**

Conceived and designed the experiments: CS RRN SR CB UMB. Performed the experiments: CS RRN SR. Analyzed the data: CS RRN SR CB UMB. Contributed reagents/materials/analysis tools: CB. Wrote the paper: UMB.

**References**

1. Di Lorenzo A, Bedford MT. Histone arginine methylation. FEBS Lett. 2011; 585: 2024–2031. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21074527](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21074527) doi: 10.1016/j.febio.2010.11.010 PMID: 21074527

2. Gayatri S, Bedford MT. Readers of histone methylarginine marks. Biochim Biophys Acta—Gene Regul Mech. Elsevier B.V.; 2014; 1839: 702–710. doi: 10.1016/bbagrm.2014.02.015

3. Frankel A, Yadav N, Lee J, Branscombe TL, Clarke S, Bedford MT. The novel human protein arginine N-methyltransferase PRMT6 is a nuclear enzyme displaying unique substrate specificity. J Biol Chem. 2002; 277: 3537–3543. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11724789 PMID: 11724789](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11724789)

4. Lakowski TM, Frankel A. A kinetic study of human protein arginine N-methyltransferase 6 reveals a distributive mechanism. J Biol Chem. 2008; 283: 10015–10025. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18263580 PMID: 18263580](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18263580)

5. Hylus D, Stein C, Schnabel K, Schlitz E, Imhof A, Dou Y, et al. PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev. 2007; 21: 3369–3380. PMID: 18079182

6. Thandapani P, O’Connor TR, Bailey TL, Richard S. Defining the RGG/RG motif. Mol Cell. 2013; 50: 613–623. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23746349 PMID: 23746349](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23746349)

7. Miranda TB, Webb KJ, Edberg DD, Reeves R, Clarke S. Protein arginine methyltransferase 6 specifically methylates the nonhistone chromatin protein HMGA1a. Biochem Biophys Res Commun. 2005; 336: 831–835. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16157300 PMID: 16157300](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16157300)

8. Sgarra R, Lee J, Tessari MA, Altamura S, Spolaore B, Giancotti V, et al. The AT-hook of the chromatin architectural transcription factor high mobility group A1a is arginine-methylated by protein arginine methyltransferase 6. J Biol Chem. 2006; 281: 3764–3772. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16293633 PMID: 16293633](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16293633)

9. Boulanger MC, Liang C, Russell RS, Lin R, Bedford MT, Wainberg MA, et al. Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol. 2005; 79: 124–131. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15596808 PMID: 15596808](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15596808)

10. Singhroy DN, Mesplede T, Sabbah A, Quashie PK, Falgueyret JP, Wainberg MA. Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity. Retrovirology. 2013; 10: 73. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23866860 PMID: 23866860](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23866860)

11. El-Andaloussi N, Valovka T, Toueille M, Steinacher R, Focke F, Gehrig P, et al. Arginine methylation regulates DNA polymerase beta. Mol Cell. 2006; 22: 51–62. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16600869 PMID: 16600869](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16600869)

12. Scaramuzzino C, Casci I, Parodi S, Lievens PMJ, Polanco MJ, Millo M, et al. Protein Arginine Methyltransferase 6 Enhances Polyglutamine-Expanded Androgen Receptor Function and Toxicity in Spinal and Bulbar Muscular Atrophy. Neuron. The Authors; 2015; 85: 88–100. doi: 10.1016/j.neuron.2014.12.031 PMID: 25569348

13. Guccione E, Bassi C, Casadio F, Martinato F, Cesaroni M, Schuchlautz H, et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature. 2007; 449: 933–937. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17898714 PMID: 17898714](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17898714)

14. Waldmann T, Izzo A, Kamieniarz K, Richter F, Vogler C, Sarg B, et al. Methylation of H2AR29 is a novel repressive PRMT6 target. Epigenetics Chromatin. 2011; 4: 11. Available: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17898714 PMID: 17898714](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17898714)
PRMT6 Cooperates with Polycomb Proteins in Gene Expression

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18682226 doi: 10.1016/j.str.2008.04.015 PMID: 18682226
Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18077460 PMID: 18077460

15. Casadio F, Lu X, Pollock SB, LeRoy G, Garcia BA, Muir TW, et al. H3R42me2a is a histone modification with positive transcriptional effects. Proc Natl Acad Sci U S A. 2013; 110: 14894–14899. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23980157 doi: 10.1073/pnas.1312251110 PMID: 23980157

16. Stein C, Riedl S, Ruthnick D, Notzold RR, Bauer UM. The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes. Nucleic Acids Res. 2012; 40: 9522–9533. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22904088 doi: 10.1093/nar/gks767 PMID: 22904088

17. Phakie S, Mzoughi S, Bezzi M, Jennifer N, Mok WC, Low DH, et al. p53-independent regulation of p21/Waf1/Cip1 expression and senescence by PRMT6. Nucleic Acids Res. 2012; 40: 9534–9542. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22987071 doi: 10.1093/nar/gks858 PMID: 22987071

18. Neault M, Mallette FA, Vogel G, Michaud-Levesque J, Richard S. Ablation of PRMT6 reveals a role as a negative transcriptional regulator of the p53 tumor suppressor. Nucleic Acids Res. 2012; 40: 9513–9521. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22904064 doi: 10.1093/nar/gks764 PMID: 22904064

19. Kleinschmidt MA, de Graaf P, van Teeffelen HA, Timmers HT. Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors. PLoS One. 2012; 7: e41446. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22916108 doi: 10.1371/journal.pone.0041446 PMID: 22916108

20. Iberg AN, Espejo A, Cheng D, Kim D, Michaud-Levesque J, Richard S, et al. Arginine methylation of the histone H3 tail impedes effector binding. J Biol Chem. 2008; 283: 3006–3010. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18077460 PMID: 18077460

21. Couture JF, Collazo E, Trievel RC. Molecular recognition of histone H3 by the WD40 protein WDR5. Nat Struct Mol Biol. 2006; 13: 698–703. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16829960 PMID: 16829960

22. Ruthenburg AJ, Wang W, Graybosch DM, Li H, Allis CD, Patel DJ, et al. Histone H3 recognition and presentation by the WDR5 module of the MLL1 complex. Nat Struct Mol Biol. 2006; 13: 704–712. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16829959 PMID: 16829959

23. Michaud-Levesque J, Richard S. Thrombospondin-1 is a transcriptional repression target of PRMT6. J Biol Chem. 2009; 284: 21338–21346. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19509293 doi: 10.1074/jbc.M109.005322 PMID: 19509293

24. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell. 2007; 129: 823–837. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17512414 doi: 10.1016/j.str.2006.10.013 PMID: 17512414

25. Rosenfeld Ja, Wang Z, Schones DE, Zhao K, DeSalle R, Zhang MQ. Determination of enriched histone modifications in non-genic portions of the human genome. BMC Genomics. 2009; 10: 143. doi: 10.1186/1471-2164-10-143 PMID: 19335899

26. van Ingen H, van Schaik FM, Wierik H, Ballering J, Rehmman H, Dechesne AC, et al. Structural insight into the recognition of the H3K4me3 mark by the TFIID subunit TAF3. Structure. 2008; 16: 1245–1256. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17703709 PMID: 17703709

27. Vermeulen M, Mulder KW, Denissen S, Pijnappel WW, van Schaik FM, Varier RA, et al. Selective anchoring of TFIID to nucleosomes by trimethylation of histone H3 lysine 4. Cell. 2007; 131: 58–69. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17884155 PMID: 17884155

28. Guccione E, Martinao F, Finocchiaro G, Luzi L, Tizzoni L, Dali F, Olio V, et al. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol. 2006; 8: 764–770. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16767079 PMID: 16767079

29. Kuvardina ON, Herglotz J, Kolodziej S, Kohrs N, Herkt S, Wojcik B, et al. RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation. Blood. 2015; 125: 3570–3580. doi: 10.1182/blood-2014-11-510519 PMID: 25911237
30. Herglotz J, Kuvardina ON, Kolodziej S, Kumar A, Hussong H, Grez M, et al. Histone arginine methylation keeps RUNX1 target genes in an intermediate state. Oncogene. 2013; 32: 2565–2575. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22777353 doi: 10.1038/onc.2012.274 PMID: 22777353

31. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011; 469: 343–349. doi: 10.1038/nature09784 PMID: 21248841

32. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (80-). 2002; 298: 1039–1043. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12351676 PMID: 12351676

33. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 2002; 16: 2893–2905. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12435631 PMID: 12435631

34. Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, et al. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell. 2002; 111: 197–208. doi: 10.1016/S0092-8674(02)00976-5 PMID: 12408864

35. Levine SS, Weiss A, Erdjument-Bromage H, Shao Z, Tempst P, Kingston RE. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol. 2002; 22: 6070–6076. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12167701 PMID: 12167701

36. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 2006; 20: 1123–1136. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16618801 PMID: 16618801

37. Suzuki M, Mizutani-Koseki Y, Fujimura Y, Miyagishima H, Kaneko T, Takada Y, et al. Involvement of the Polycomb-group gene Ring1B in the specification of the anterior-posterior axis in mice. Development. 2002; 129: 4171–4183. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12183370 PMID: 12183370

38. Miyagishima H, Isoko K, Fujimura Y, Iyo M, Takihara Y, Masumoto H, et al. Dissociation of mammalian Polycomb-group proteins, Ring1B and Rae28/Ph1, from the chromatin correlates with configuration changes of the chromatin in mitotic and meiotic prophase. Histochem Cell Biol. 2003; 120: 111–119. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12883906 PMID: 12883906

39. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 2007; 21: 525–530. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17344414 PMID: 17344414

40. Ren X, Vincenz C, Kerppola TK. Changes in the distributions and dynamics of polycomb repressive complexes during embryonic stem cell differentiation. Mol Cell Biol. 2008; 28: 2884–2895. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18316406 doi: 10.1128/MCB.00949-07 PMID: 18316406

41. Pasini D, Bracken AP, Jensen MR, Lazzerini Denchi E, Helin K. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. Embo J. 2004; 23: 4061–4064. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15385962 PMID: 15385962

42. Schoorlemmer J, Marcos-Gutierrez C, Were F, Martinez R, Garcia E, Satijn DP, et al. Ring1A is a transcriptional repressor that interacts with the Polycomb-M33 protein and is expressed at rhombomere boundaries in the mouse hindbrain. Embo J. 1997; 16: 5930–5942. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9312051 PMID: 9312051

43. Nomura M, Takihara Y, Shimada K. Isolation and characterization of retinoic acid-inducible cDNA clones in F9 cells: one of the early inducible clones encodes a novel protein sharing several highly homologous regions with a Drosophila polyhomeotic protein. Differentiation. 1994; 57: 39–50. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8070621 PMID: 8070621

44. Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006; 441: 349–353. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16625203 PMID: 16625203

45. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell. 2006; 125: 301–313. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16625203 PMID: 16625203
46. Boncinelli E, Simeone a, Acampora D, Mavilio F. HOX gene activation by retinoic acid. Trends Genet. 1991; 7: 329–34. Available: http://www.ncbi.nlm.nih.gov/pubmed/1685814 PMID: 1685814
47. Andrews PW. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol. 1984; 103: 285–293. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6144603 PMID: 6144603
48. Houldsworth J, Heath SC, Bosi GJ, Studer L, Chaganti RSK. Expression profiling of lineage differentiation in pluripotential human embryonal carcinoma cells. Cell Growth Differ. 2002; 13: 257–264. PMID: 12114215
49. Tavares L, Dimitrova E, Oxley D, Webster J, Poot R, Demmers J, et al. RYBP-PRC1 Complexes Mediate H2A Ubiquitylation at Polycomb Target Sites Independently of PRC2 and H3K27me3. Cell. 2012; 148: 664–678. doi:10.1016/j.cell.2011.12.029 PMID: 22325148
50. Gao Z, Zhang J, Bonasio R, Strino F, Sawai A, Parisi F, et al. PCGF Homologs, CBX Proteins, and RYBP Define Functionally Distinct PRC1 Family Complexes. Mol Cell. Elsevier Inc.; 2012; 45: 344–356. doi: 10.1016/j.molcel.2011.03.025 PMID: 21549310
51. Schmitges FW, Prusty AB, Faty M, Stutzer A, Lingaraju GM, Aiwazian J, et al. Histone methylation by PRC2 is inhibited by active chromatin marks. Mol Cell. 2011; 42: 330–341. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21549310 doi: 10.1016/j.molcel.2011.03.025 PMID: 21549310
52. Lee YH, Ma H, Tan TZ, Nq SS, Soong R, Mori S, et al. Protein arginine methyltransferase 6 regulates embryonic stem cell identity. Stem Cells Dev. 2012; 21: 2613–2622. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=22455726 doi: 10.1089/scd.2011.0330 PMID: 22455726
53. McKee AE, Minet E, Stem C, Riahi S, Stiles CD, Silver PA. A genome-wide in situ hybridization map of RNA-binding proteins reveals anatomically restricted expression in the developing mouse brain. BMC Dev Biol. 2005; 5: 14. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16033648 PMID: 16033648
54. Xu M, Zhao G-N, Lv X, Liu G, Wang LY, Hao D-L, et al. CTCF Controls HOXA Cluster Silencing and Mediates PRC2-Repressive Higher-Order Chromatin Structure in NT2/D1 Cells. Mol Cell Biol. 2014; 34: 3867–3879. doi: 10.1128/MCB.00567-14 PMID: 25135475
55. Xu M, Zhao G-N, Lv X, Liu G, Wang LY, Hao D-L, et al. CTCF Controls HOXA Cluster Silencing and Mediates PRC2-Repressive Higher-Order Chromatin Structure in NT2/D1 Cells. Mol Cell Biol. 2014; 34: 3867–3879. doi: 10.1128/MCB.00567-14 PMID: 25135475